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Abstract 
Background: Daily use of high potency cannabis has been reported to carry a high risk for psychotic disorder. However, the evidence 
is mixed on whether any pattern of cannabis use is associated with a particular symptomatology in first episode psychosis (FEP) 
patients. 
Method: We analysed data from 901 patients and 1235 controls recruited across six countries, as part of the European Network of 
National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study. We used item response modelling to 
estimate two bifactor models, which included general and specific dimensions of psychotic symptoms in patients and psychotic 
experiences in controls. The associations between these dimensions and cannabis use were evaluated using linear mixed effects 
models analyses. 
Results: In patients, there was a linear relationship between the positive symptom dimension and the extent of lifetime exposure to 
cannabis, with daily users of high potency cannabis having the highest score (B=0.35; 95%CI 0.14 to 0.56). Moreover, negative 
symptoms were more common among patients who never used cannabis compared with those with any pattern of use (B=-0.22; 
95%CI -0.37 to -0.07). In controls, psychotic experiences were associated with current use of cannabis but not with the extent of 
lifetime use. Neither patients nor controls presented differences in depressive dimension related to cannabis use. 
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Conclusions: Our findings provide the first large scale evidence that first episode psychotic patients with a history of daily use of 
high potency cannabis present with more positive and less negative symptoms than those who never used cannabis or used low 
potency types. 
 
Keywords 
Cannabis use; symptom dimensions; psychopathology; psychotic experiences; cannabis-associated psychosis 
 
Introduction 
There is compelling evidence suggesting that cannabis use is associated with psychotic disorders (Marconi et al., 2016). However, it 
is unclear whether cannabis use is a ‘modifier’ factor for psychotic disorders, which affects symptom presentation. The existence of 
a pattern of psychotic symptomatology particularly associated with cannabis has been described in several case series (Walter 
Bromberg, 1934, Talbott and Teague, 1969, Spencer, 1971, Bernhardson and Gunne, 1972, Chopra and Smith, 1974). Nevertheless, 
case and cohort studies have found mixed results as to whether (Negrete et al., 1986, Peralta and Cuesta, 1992, Bersani et al., 2002, 
Green et al., 2004, Grech et al., 2005, Addington and Addington, 2007, Foti et al., 2010, Ringen et al., 2016, Seddon et al., 2016)  or 
not (Thornicroft et al., 1992, Stirling et al., 2005, Dubertret et al., 2006, Boydell et al., 2007, van Dijk et al., 2012, Tosato et al., 2013, 
Barrowclough et al., 2015) psychotic patients using cannabis present with more positive symptoms than those not using cannabis. 
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Moreover, there is mixed evidence of any relationship between cannabis use and negative symptoms in psychosis. Some reports 
suggest fewer negative symptoms in psychotic patients that use cannabis (Peralta and Cuesta, 1992, Bersani et al., 2002, Green et 
al., 2004), which is consistent with having enough social skills to obtain the substance (Murray et al., 2017). However, this association 
has not been confirmed in other studies (Grech et al., 2005, Seddon et al., 2016) and others even reported a positive association 
(Ringen et al., 2016). 
These inconsistencies might be explained by differences in study design and methods. For example, only a few findings were based 
on first episode psychosis (FEP) patients (Grech et al., 2005, Addington and Addington, 2007, Tosato et al., 2013, Seddon et al., 
2016), which minimize selection and recall bias, and the confounding effect of antipsychotic drugs on symptoms. In addition, a 
metanalysis of longitudinal studies concluded that most results lacked sufficient power to detect an effect of cannabis on symptoms, 
or inadequately controlled for potential confounders (Zammit et al., 2008). Furthermore, although a few studies included information 
on frequency of use, all failed to obtain detailed information on the lifetime pattern of cannabis use, especially on the type and strength 
of cannabis used. Of note, potent cannabis varieties, with high concentrations of Delta-9-Tetrahydrocannabinol (Δ9-THC), have been 
associated with the most harm to mental health (Di Forti et al., 2015, Freeman et al., 2018) and, in recent years, these potent types 
have become more available worldwide (ElSohly et al., 2016, Potter et al., 2018, Freeman et al., 2019). Finally, no studies have used 
factor analysis of observed symptoms to evaluate to what extent cannabis use is a factor influencing the clinical heterogeneity of 
psychosis. 
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On the other hand, in the general population there are consistent findings regarding the association between cannabis use and 
psychotic experiences (Ragazzi et al., 2018). However, most studies had limited geographical coverage and the examined population 
was scarcely representative of the population at risk of psychosis (Ragazzi et al., 2018). 
In this study, we set out to clarify the association between detailed patterns of cannabis use and transdiagnostic symptom dimensions 
in a large multinational FEP sample. In addition, we examine the association between detailed patterns of cannabis use and 
subclinical symptom dimensions in a large sample of controls representative of the population at risk in each catchment area. 
Specifically, we sought to test the hypotheses that: (1) positive psychotic symptoms are more common among FEP patients with 
more frequent lifetime use of cannabis and greater exposure to use of high potency varieties; (2) positive psychotic experiences are 
more common in population controls with a recent use of cannabis, who would be more resilient to the long-term effects of cannabis; 
(3) negative symptoms are more common among those patients who have never used cannabis. 
 
Methods 
Study design and participants 
This analysis is based on the incidence and case-control study work package of the EUropean network of national schizophrenia 
networks studying Gene-Environment Interactions (EU-GEI). 
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FEP individuals were identified between 2010 and 2015 across six countries to examine incidence rates of schizophrenia and other 
psychotic disorders (Jongsma et al., 2018), and symptomatology at psychosis onset (Quattrone et al., 2019). For examining risk 
factors, we sought to perform an extensive assessment on approximately 1,000 FEP patients and 1,000 population-based controls 
during the same time period. 
Patients were included in the case-control study if they met the following criteria during the recruitment period: (a) aged between 18 
and 64 years; (b) presentation with a clinical diagnosis for an untreated FEP, even if longstanding [International Statistical 
Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes F20-F33]; (c) resident within the catchment 
area. Exclusion criteria were: (a) previous contact with psychiatric services for psychosis; (b) psychotic symptoms originating from an 
identified organic condition; and (c) transient psychotic symptoms resulting from acute intoxication (ICD-10: F1x.5).  
The recruitment of controls followed a mixture of random and quota sampling methods, in order to achieve the best possible 
representativeness in age, sex, and ethnicity of the population living in each catchment area. The identification process varied by site 
and was based on locally available sampling frames, including mostly the use of lists of all postal addresses and general practitioners’ 
lists from randomly selected surgeries. When these resources were not fully available, internet and newspapers advertising were 
used to fill quotas. Exclusion criteria for controls were: (a) diagnosis of a psychotic disorder; (b) ever having been treated for psychotic 
symptoms. 
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We analysed data from eleven catchment areas, including urban and less urban populations (i.e. Southeast London, Cambridgeshire 
and Peterborough (England); central Amsterdam, Gouda and Voorhout (the Netherlands); Bologna municipality, city of Palermo 
(Italy); Paris [Val-de-Marne], Puy-de-Dôme (France); Madrid [Vallecas], Barcelona (Spain); and Ribeirão Preto (Brazil). Further 
information on the case-control sample and the recruitment strategies is included in the supplementary material. 
Measures 
Data on age, sex, and ethnicity were collected using a modified version of the Medical Research Council Sociodemographic Schedule 
(Mallett, 1997). The OPerational CRITeria (OPCRIT) system (McGuffin et al., 1991) was used by centrally trained investigators, 
whose reliability was assessed before and throughout the study (k=0.7), to assess psychopathology in the first four weeks after the 
onset and generate research-based diagnoses based on different diagnostic classification systems. The Community Assessment of 
Psychic Experiences (CAPE) (Stefanis et al., 2002) was administered to controls to self-report their psychotic experiences. The 
reliability of the CAPE is good for all the languages spoken in the countries forming part of the EU-GEI study 
(http://cape42.homestead.com). 
A modified version of the Cannabis Experience Questionnaire (CEQEU-GEI) (Di Forti et al., 2009) was used by investigators to collect 
extensive information on the patterns of use of cannabis and other drugs. We used six measures of cannabis use (Supplementary 
Table S2), including a variable measuring specific patterns of cannabis exposure by combining the frequency of use with the potency 
of cannabis. As illustrated in the supplementary material, the cannabis potency variable was based on the data published in the 
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European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (European Monitoring Centre for Drugs and Drug Addiction, 
2013, Di Forti et al., 2019). 
We selected confounders based on their possible association with cannabis use and/or symptom dimensions. These included: sex; 
age; ethnicity; use of stimulants, hallucinogens, ketamine, cocaine, crack, and novel psychoactive substances; current use of 
cigarettes (smoking 10 cigarettes or more per day=1), and current use of alcohol (drinking 10 alcohol units or more per week=1).  
Statistical analysis 
Dimensions of psychotic symptoms in patients and psychotic experiences in controls 
Data from OPCRIT and CAPE were analysed using multidimensional item response modelling in Mplus, version 7.4 (Muthén and 
Muthén, 2012), to estimate two bifactor models, based on the associations among observer ratings of psychotic symptoms in patients 
and self-ratings of psychotic experiences in controls. This methodology is described in full in our EU-GEI paper on symptom 
dimensions in FEP patients (Quattrone et al., 2019), and it was likewise applied to psychotic experiences in population controls. 
Briefly, CAPE items were dichotomized as 0 ‘absent’ or 1 ‘present’. In order to ensure sufficient covariance coverage for item response 
modelling, we used items with a valid frequency of ‘present’ ≥10% in our sample, and we excluded items with low correlation values 
(<.3) based on the examination of the item correlation matrix. As in the previous analysis in patients, the bifactor solution was 
compared with other solutions (i.e., unidimensional, multidimensional, and hierarchical models) using Log-Likelihood (LL), Akaike 
Information Criterion (AIC), Bayesian Information Criterion (BIC), and Sample-size Adjusted BIC (SABIC) as model fit statistics. Path 
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diagrams that illustrate these models are presented in Supplementary Figure S1. Reliability and strength indices such as McDonald’s 
omega (ω) (Rodriguez et al., 2016), omega hierarchical (ωH) (Rodriguez et al., 2016), and index H (Hancock and Mueller, 2001), 
were computed to determine: 1) the proportion of common variance accounted by general and specific symptom dimensions; 2) the 
proportion of reliable variance accounted by the general dimension not unduly affected by the specific dimensions; 3) the proportion 
of reliable variance accounted for by each specific dimension not unduly affected by the general and all the other specific dimensions; 
4) the overall reliability and replicability of the bifactor construct of psychosis-like experiences. Finally, we generated factor scores for 
one general psychotic experience dimension and three specific dimensions of positive, negative, and depressive psychotic 
experiences. 
For patients, we used the previously generated factor scores for one general psychosis dimension and five specific dimensions of 
positive, negative, disorganised, manic, and depressive symptoms (Quattrone et al., 2019).  
Symptom dimensions and cannabis use 
We evaluated the relationship between psychotic symptom dimensions in patients, or psychotic experience dimensions in controls, 
and cannabis use using linear mixed effects models in STATA14 (StataCorp, 2015). We specifically modelled symptom dimension 
scores as a function of each of the six measures of cannabis use. We then evaluated the combined effect of frequency of use and 
potency of cannabis. To account for the non-independence of symptom profiles of subjects assessed within the same country (for 
example, due to cultural similarities), and for the potential within-site correlation (for example, due to context factors), we fitted a 
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three-level mixed model, where the random effect encompassed two levels of random intercepts: one due to the countries, and 
another due to the sites within the countries. Finally, we used the Benjamini-Hochberg (B-H) procedure to reduce the false discovery 
rate, which we set at 5%.  
 
Results 
Sample characteristics 
We analysed data from 901 FEP patients and 1,235 controls. The main socio-demographic characteristics and history of substance 
misuse of patients and controls are presented in Supplementary Table S1. Supplementary Tables S3 and S5 show the sample 
prevalence of psychotic experiences in controls and of psychotic symptoms in patients. 
Bifactor model of psychotic experiences in controls 
Supplementary Table S4 shows that, as in our previous analysis of the OPCRIT items (Quattrone et al., 2019), the bifactor model 
provided the best fit for the CAPE items, as illustrated by AIC, BIC and SABIC substantially lower compared with competing models. 
This solution explained 60% of the unique variance. In addition, Figure 1 shows that, within the bifactor model, the explained variance 
was due to individual differences mostly on the general psychotic experience dimension. This is illustrated by the relative omega 
coefficient, which, for example, showed that 85% of the reliable variance was due to the general dimension when partitioning out the 
variability in scores due to the specific dimensions. Moreover, factor loadings of moderate to high magnitude were observed for most 
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items on the general psychotic experience dimension, whereas factor loadings of a smaller magnitude were observed for the specific 
dimensions (Figure 1). Consistently, the index H, which is a measure of the construct reliability and replicability across studies 
(Hancock and Mueller, 2001), was very high for the general dimension (0.92), moderate for positive (0.78) and negative (0.71) 
dimensions and lower for the depressive dimension (0.41).  
 
Symptom dimensions in patients by pattern of cannabis use  
Models’ results are presented in Table 1.1 which shows that: 
1) There were no differences in the distribution of positive symptoms according to early age at first use (=<15 years old), nor, after 
B-H correction, according to ever or current use of cannabis. However, positive symptoms were more common among patients who 
spent more than 20 euros per week on cannabis (B=0.3; 95%CI 0.11 to 0.48; p=0.001). 
2) Fewer negative symptoms were observed among those patients who used cannabis at least once compared with those who never 
tried (B=-0.22; 95%CI -0.37 to -0.07; p=0.004). Early age at first use and current use of cannabis was not associated with negative 
symptomatology. 
3) Manic symptoms were more frequent among patients who had ever used cannabis (B=0.22; 95%CI 0.08 to 0.36; p=0.002). 
4) There were no differences in the distribution of the scores on the depressive, disorganization and general psychosis dimensions 
according to any measure of cannabis use. 
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Psychotic experience dimensions in population controls by patterns of cannabis use 
Models’ results are presented in Table 1.2, which shows that: 
1) There were no differences in the distribution of positive psychotic experiences according to ever use of cannabis or early age at 
first use (=<15 years old). However, positive psychotic experiences were more commonly reported by subjects who currently used 
cannabis (B=0.33; 95%CI 0.15 to 0.51; p<0.001) and who spent more than 20 euros per week on cannabis (B=0.39; 95%CI 0.09 to 
0.69; p=0.011).  
2) There were no differences in the distribution of the depressive and negative experiences in population controls according to 
cannabis use. 
 
Symptom dimensions by frequency of use and potency of cannabis 
The independent effects of frequency of use and potency of cannabis is reported in Supplementary Tables S6.1 and S6.2, and 
Supplementary Figure S2, showing that, only in patients, positive symptoms were more common in those who used cannabis on a 
daily basis and exposed to high potency varieties  
Testing the combined ‘type-frequency’ variable in patients, we found evidence of a linear relationship between the positive symptom 
dimension and the extent of exposure to cannabis, with daily users of high potency cannabis showing the highest score (B=0.35; 
95%CI 0.14 to 0.56; p=0.001). Therefore, we introduced a contrast operator and plotted the exposure-response relationship for 
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positive symptoms (Figure 2), by comparing the predictive margins of the adjusted mean of each group against the grand adjusted 
mean of all groups. Figure 2 shows that the adjusted mean for daily users of high potency cannabis was 0.2 units greater than the 
grand adjusted mean. Moreover, the adjusted means for the groups who never or rarely used cannabis were respectively 0.16 or 
0.18 units lower than the grand adjusted mean. 
A negative relationship between the negative symptom dimension score and patterns of cannabis use was also observed in patients. 
Figure 3 shows that patients with psychosis who never used cannabis had more negative symptoms either compared with the grand 
adjusted mean or with any pattern of cannabis use. 
 
Discussion 
Principal findings 
This is the first multinational study analysing data on the potency of the cannabis used by FEP patients to investigate a dose effect 
relationship between cannabis use and dimensions of symptoms, and also its effect on dimensions of psychotic experiences in 
population controls. We provide the first evidence that: 1) in patients, a positive correlation exists between the extent of premorbid 
cannabis use and the score on the positive symptom dimension, with daily users of high potency cannabis showing the most positive 
symptoms at FEP; 2) psychotic experiences in non-clinical populations are associated with current use of cannabis but are 
independent of the extent of lifetime exposure to cannabis; 3) negative symptoms at FEP are more common in patients who have 
never tried cannabis; 4) depressive symptoms are independent of any pattern of use of cannabis.  
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Limitations 
Our findings must be considered in the context of two main limitations. First, individual data on patterns of cannabis use are not 
validated with biological samples. However, biological tests are not considered the gold standard method for such a validation (Large 
et al., 2012) and would not allow one to ascertain the extent of cannabis use over the years (Taylor et al., 2017). Moreover, studies 
combining self-report and laboratory data support the reliability of subjects in reporting the type of cannabis they use (Wolford et al., 
1999, Freeman et al., 2014). Second, we did not take into account the cannabidiol (CBD) contribution to the potency variable, as 
official data on its content in the different cannabis varieties were not available in most study sites; CBD might counterbalance Δ9-
THC effects and minimise both psychotic experiences (Schubart et al., 2011) and symptoms (McGuire et al., 2018).  
Comparison with previous research 
We extend previous research on cannabis and psychotic symptoms to a multinational sample confirming the association between 
cannabis use and positive symptoms of  FEP (Ringen et al., 2016, Seddon et al., 2016). Our results are in line with Schoeler et al. 
(2016), who carefully scrutinised the literature on the effect of continuation of cannabis use after FEP, concluding that this would be 
associated with a more severe positive symptomatology (Schoeler et al., 2016). That said, any comparison with previous research is 
limited by the lack of information on frequency and potency in all the previous studies along with subjects’ exposure to more potent 
varieties of cannabis in recent years (Potter et al., 2018). In this respect, we firstly provide some evidence that cannabis affects 
positive symptoms in a dose response manner, further supporting the converging epidemiological and experimental evidence that 
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the use of cannabis with high content of Δ9-THC has a more detrimental effect than other varieties (Di Forti et al., 2009, Morrison et 
al., 2009, Freeman et al., 2018). 
We also report evidence in a multinational FEP sample of an association between lifetime cannabis use and fewer negative 
symptoms, the latter often considered as a marker of greater neurodevelopmental impairment in psychotic subjects. Two opposite 
interpretations should be discussed.  
First, some authors have suggested that people with a psychotic disorder might use cannabis as an attempt to self-medicate negative 
symptoms, and thus the observed reduction in negative symptomatology would be an epiphenomenon due to the cannabis intake 
itself (Peralta and Cuesta, 1992).  
Second, psychotic disorders may be characterized by less neurodevelopmental features when associated with cannabis use (Ruiz-
Veguilla et al., 2012, Ferraro et al., 2013, Murray et al., 2017, Ferraro et al., 2019), hence FEP patients who do not initiate to use 
cannabis would have more negative symptoms.  
The lack of a dose dependency in our study appears to speak against the first and in favour of the second possibility, as the difference 
holds between those who never obtained cannabis and those who may have used it only once. Moreover, negative symptoms would 
reduce the social and instrumental skills that were necessary to obtain illegally cannabis and sustain its use in all the countries 
included in the study, except Holland.  
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Last, we report that the cumulative exposure to cannabis does not impact on psychotic experiences in controls. One could of course 
argue that the largest proportion of subjects with the harmful pattern of cannabis use were patients. However, further research is 
needed to look into plausible mechanisms of resilience to the psychotogenic effect of cannabis as observed in our controls, who 
report psychotic experiences if current users but do not seem to accumulate a risk over life time cannabis use and develop psychotic 
disorders.  Indeed, future studies should aim to: 1) investigate if and how genetic factors, plausibly regulating the endocannabinoid 
and dopamine systems, pose a small subset of cannabis users at high risk of developing a psychotic disorders with particular 
symptomatology; 2) clarify over the course of the disorder whether or not differences in symptomatology between current and former 
cannabis users may be related to residual cannabis effects. 
Implications 
The novelty of our study is based on our examination of data on lifetime frequency of cannabis use and on the type of the cannabis 
used; high potency types are increasing worldwide. For instance, a recent potency study revealed that in London, the high potency 
type of cannabis called skunk has now taken up 96% of the street market (Potter et al., 2018). The EMCDDA has described a 
European cannabis market characterised by potent varieties (European Monitoring Centre for Drugs and Drug Addiction, 2013) Iike 
those present in Amsterdam coffee shops that can reach up to 39% of THC. Indeed, as daily use, and use of high potency cannabis, 
have been associated both with greatest risk to develop psychotic disorders and to high rates of psychotic disorders across Europe 
(Di Forti et al., 2019), here we show that in FEP patients daily use of high potency cannabis drives a high score on the positive 
 19 
symptom dimension. Further research should aim to determine biological mechanisms underlying how cannabis impacts on different 
clinical manifestations of psychosis. Meanwhile, translating current findings into clinical practice, symptom dimension scores can be 
used to stratify patients and develop secondary prevention schemes for cannabis-associated psychosis.  
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Figure 1. Bifactor model of psychotic experiences in controls 
 28 
 
 
(£) Observed variables (No. of CAPE items); () Unobserved variables (latent factors); (") standardized item loading estimation onto latent factors; G, general 
psychosis-like factor; Specific psychotic experiences factors: DEP, Depression; NEG, Negative; POS, Positive. Reliability and strenght estimates: H=construct 
reliability index; ω= McDonald omega; ωH=hierarchical omega; ω/ωH= Relative omega.  
Explanatory note: McDonald‘s ω is an estimate of the proportion of the common variance accounted by general and specific symptom dimensions.(Rodriguez 
et al., 2016). Relative omega (ω/ωh) is the amount of reliable variance explained in the observed scores attributable to a) the general factor independently from 
the specific symptom dimensions, and 2) each specific symptom dimension independently from the general factor. 
H is an index of the quality of the measurement model based on the set of CAPE items for each dimension.(Hancock and Mueller, 2001) Indices can range 
from 0 to 1, with values closer to 1 indicating a better construct reliability and replicability across studies. 
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 1 
Figure 2. Positive symptom dimension in cases by patterns of cannabis use. 2 
 3 
Figure 2 shows the contrasts of the positive symptom dimension predicted mean of each group of 4 
patterns of use of cannabis against the predicted grand mean of all groups (represented by the red 5 
line). The positive value for the contrast of the daily use of high potency cannabis indicates more positive 6 
symptomatology in this group. On the other hand, negative values for the contrasts of the first two 7 
groups indicates less positive symptomatology when there is less exposure to cannabis. These 8 
differences are statistically significant, as indicated by 95% confidence intervals that do not overlap with 9 
zero. The model was a random intercept model which allowed symptoms to vary across countries and 10 
sites within countries, but it assumed that frequency of use and type of cannabis had an individual fixed 11 
effect. Values were adjusted for age, sex, ethnicity, diagnosis, and use of other recreational/illicit 12 
substances. 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
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 24 
 25 
 30 
 26 
Figure 3. Negative symptom dimension in cases by patterns of cannabis use. 27 
 28 
Figure 3 shows the contrasts of the negative symptom dimension predicted mean of each group of 29 
patterns of use of cannabis against the grand adjusted predicted mean (represented by the red line). 30 
Subjects who had never used cannabis presented with more negative symptoms compared to the whole 31 
sample. The model was a random intercept model which allowed symptoms to vary across countries 32 
and sites within countries, but it assumed that frequency of use and type of cannabis had an individual 33 
fixed effect. 34 
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